Background
Digitalis is a plant-derived cardiac glycoside commonly used in the treatment of congestive heart failure, atrial fibrillation, and reentrant SVT.[1, 2] Digoxin is the only available preparation of digitalis in the United States.
Cardiac glycoside poisoning continues to be a problem in the United States because of the wide availability of digoxin and the narrow therapeutic window. Although most digoxin toxicity occurs in the adult population, acute cardiac glycoside toxicity is well described in the pediatric literature.[3, 4] Digoxin-specific fragment antigen binding (Fab) antibody fragments have contributed significantly to the improved morbidity and mortality of toxic patients since their approval in 1986 by the US Food and Drug Administration (FDA).
In 1980, digoxin was one of the 10 most commonly prescribed drugs in the United States. Although its use has declined in recent years[5] , it is still among the top 50 prescribed drugs in the United States.[6] Digitalislike compounds are also found in certain plants, such as the common oleander, foxglove, yew berry, dogbane, lily of the valley, and red squill, as well as certain toad species. Herbal exposure usually occurs through the ingestion of plants or the inhalation of smoke from burning plants. Cardiac glycosides account for 2.6% of toxic plant exposures in the United States.[7, 8] Most of these exposures are in children.[8]
Pathophysiology
Digitalis has effects on both the automaticity and inotrophy of the heart. Digitalis reversibly binds to the extracytoplasmic surface of the sodium and potassium-activated adenosine triphosphate pump (Na+ K+ ATPase). In doing so, it inhibits the active transport of sodium and potassium across the cell membrane, leading to a rise in intracellular sodium with each action potential. This causes an increase in the intracellular calcium concentration secondary to either enhanced entry or reduced efflux via the sodium-calcium exchanger.[9] By a mechanism not completely understood, the increased intracellular calcium concentration leads to improved cardiac inotropy by increasing phases 4 and 0 of the cardiac action potential. Digitalis also has negative chronotropic action, which is partly a vagal effect and partly a direct effect on the sinoatrial (SA) node.
Digitalis affects different myocardial tissue in different ways. While the atria and ventricles may exhibit increased automaticity with causatives tachydysrhythmias, nodal tissue may be slowed leading to prolonged PR interval and AV nodal block.
The therapeutic daily dose of digoxin ranges from 5-15 mcg/kg. The absorption of digoxin tablets is 70-80%; its bioavailability is 95%. The kidney excretes 60-80% of the digoxin dose unchanged. The onset of action by oral (PO) administration occurs in 30-120 minutes; the onset of action with intravenous (IV) administration occurs in 5-30 minutes. The peak effect with PO dosing is 2-6 hours, and that with IV dosing is 5-30 hours. Only 1% of the total amount of digoxin in the body is in the serum; of that amount, approximately 25% is protein bound.
Digoxin has a large volume of distribution: 6-10 L/kg in adults, 10 L/kg in neonates, and as much as 16 L/kg in infants and toddlers. At therapeutic levels, the elimination half-life is 36 hours with renal excretion. In acute digoxin intoxication in toddlers and children, the average plasma half-life is 11 hours. With acute intoxication, plasma concentrations extrapolated to time zero is lower in toddlers than in infants and older children because of their increased volume of distribution and clearance.
The lethal dose of digoxin is considered to be 20-50 times the maintenance dose taken at once. In healthy adults, a dose of less than 5 mg seldom causes severe toxicity, but a dose of more than 10 mg is almost always fatal. In the pediatric population, the ingestion of more than 4 mg or 0.3 mg/kg portends serious toxicity. However, plasma concentration does not always correlate with the risk of toxicity.[10]
Epidemiology
Frequency
United States
In 1999 the American Association of Poison Control Centers (AAPCC) reported approximately 3000 pediatric poisonings associated with cardiac glycoside.[7] Of these, most were plant ingestions (66%) and digoxin exposures (33%, including therapeutic errors, intentional, and unintentional ingestions). The number of AAPCC reported cases decreased in 2008 to 1000 plant exposures and 300 digoxin poisonings.[8] Although the number of reporting poison centers decreased in 2008, this number appears to be a true decline of poisonings related to cardiac glycoside.
Mortality/Morbidity
In 2008, there was 1 pediatric fatality in approximately 1300 cardiac glycoside exposures reported to poison control centers.[8] Overall, morbidity varies from study to study. Combined adult and pediatric data reveal that exposures to cardiac glycoside toxic plants cause no morbidity in most cases. The 2008 AAPCC report has follow-up for 518 patients exposed to digitalis-like plants. Of these, 509 had little to no clinical effects, 17 had moderate effects, and only 1 had major effects. There were no deaths. Of the data available for 1044 patients with digoxin poisoning, 422 had little to no effect, 490 had moderate effects, and 115 had major effects. There were 17 deaths, only one of which was pediatric.
Sex
Pediatric poisonings from any substance are more common in males than in females.[8, 7] However, for digoxin toxicity, a Netherlands study found no difference in incidence between pediatric males and females.[11] The adult literature suggests women may be more susceptible to adverse effects than men.[11, 12]
Age
Manifestations of digitalis toxicity vary depending on age. For instance, ventricular ectopy is most prevalent in older patients; conduction defects and supraventricular ectopic rhythms are most prevalent in younger patients. Children (≤ 19 y) account for almost 80% of plant exposures and 20% of drug toxicity/poisonings reported to the AAPCC.[8] In most of these cases, the child was younger than 6 years. One study suggests that adolescents are more susceptible to digoxin on a mg/kg basis.[3]
Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006;113:2556-2564. [Medline].
Sulafa Ali KM. Collateral effects of antiarrhythmics in pediatric age. Current Pharmaceutical Design. 2008;14:782-787. [Medline].
Woolf AD, Wenger T, Smith TW, Lovejoy FH Jr. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med. Jun 25 1992;326(26):1739-44. [Medline].
Thacker D, Sharma J. Digoxin toxicity. Clin Pediatr (Phila). Apr 2007;46(3):276-9. [Medline].
Brophy JM. Rehabilitating digoxin. Eur Heart J. Jan 2006;27(2):127-9. [Medline].
The Internet Drug Reference Top 300 Prescriptions for 2005. RxList. Available at http://www.rxlist.com/script/main/art.asp?articlekey=79509. Accessed March 4, 2010.
Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Drab A, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2000;18(5):517-74. [Medline].
Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila). Dec 2009;47(10):911-1084. [Medline].
Hauptman PJ, Kelly RA. Digitalis. Circulation. Mar 9 1999;99(9):1265-70. [Medline].
Koren G, Parker R. Interpretation of excessive serum concentrations of digoxin in children. Am J Cardiol. Apr 15 1985;55(9):1210-4. [Medline].
Aarnoudse AL, Dieleman JP, Stricker BH. Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007;30(5):431-6. [Medline].
Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. Oct 31 2002;347(18):1403-11. [Medline].
Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol. 1973;6(2):153-62. [Medline].
Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin- specific Fab antibody fragments: experience in 26 cases. N Engl J Med. Nov 25 1982;307(22):1357-62. [Medline].
Zucker AR, Lacina SJ, DasGupta DS, et al. Fab fragments of digoxin-specific antibodies used to reverse ventricular fibrillation induced by digoxin ingestion in a child. Pediatrics. Sep 1982;70(3):468-71. [Medline].
Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol. Jun 4 1992;69(18):108G-118G; disc. 118G-119G. [Medline].
Brubacher JR, Ravikumar PR, Bania T, Heller MB, Hoffman RS. Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest. Nov 1996;110(5):1282-8. [Medline].
Rajapakse S. Management of yellow oleander poisoning. Clin Toxicol (Phila). Mar 2009;47(3):206-12. [Medline].
Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. Jun 1990;81(6):1744-52. [Medline].
Beller GA, Smith TW, Abelmann WH, et al. Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med. May 6 1971;284(18):989-97. [Medline].
Ekins BR, Watanabe AS. Acute digoxin poisonings: review of therapy. Am J Hosp Pharm. Mar 1978;35(3):268-77. [Medline].
Fazio A. Fab fragments in the treatment of digoxin overdose: pediatric considerations. South Med J. Dec 1987;80(12):1553-6. [Medline].
Hastreiter AR, van der Horst RL, Chow-Tung E. Digitalis toxicity in infants and children. Pediatr Cardiol. Apr-Jun 1984;5(2):131-48. [Medline].
Husby P, Farstad M, Brock-Utne JG, et al. Immediate control of life-threatening digoxin intoxication in a child by use of digoxin-specific antibody fragments (Fab). Paediatr Anaesth. Jul 2003;13(6):541-9. [Medline].
Kaufman J, Leikin J, Kendzierski D, Polin K. Use of digoxin Fab immune fragments in a seven-day-old infant. Pediatr Emerg Care. Jun 1990;6(2):118-21. [Medline].
Lewander WJ, Gaudreault P, Einhorn A, et al. Acute pediatric digoxin ingestion. A ten-year experience. Am J Dis Child. Aug 1986;140(8):770-3. [Medline].
Ordog GJ, Benaron S, Bhasin V, et al. Serum digoxin levels and mortality in 5,100 patients. Ann Emerg Med. Jan 1987;16(1):32-9. [Medline].
Rutledge J. Digitalis toxicity in infants and plasma digoxin levels. Pediatr Cardiol. 1985;6(1):51-2. [Medline].
Shumaik GM, Wu AW, Ping AC. Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med. Jul 1988;17(7):732-5. [Medline].

